{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:54:52Z","timestamp":1790927692446,"version":"4.1.0"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sanming Project of Medicine in Shenzhen","award":["SZSM202411003"],"award-info":[{"award-number":["SZSM202411003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05544-6","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:14:13Z","timestamp":1783599253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory regulation of PD-L1 protein fate in the tumor microenvironment shapes immune escape and therapeutic targeting"],"prefix":"10.1007","volume":"17","author":[{"given":"Kuan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"9","key":"5544_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A, Hu-Lieskovan S. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"issue":"6","key":"5544_CR2","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u2013201.","journal-title":"Cell Rep"},{"issue":"1","key":"5544_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10.","journal-title":"J Hematol Oncol"},{"key":"5544_CR4","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"issue":"7670","key":"5544_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature23643","volume":"549","author":"ML Burr","year":"2017","unstructured":"Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549(7670):101\u20135.","journal-title":"Nature"},{"issue":"3","key":"5544_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359\u201370.","journal-title":"Mol Cell"},{"issue":"1","key":"5544_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(1):108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w.","journal-title":"Mol Cancer"},{"issue":"2","key":"5544_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687\u201395.","journal-title":"J Clin Invest"},{"issue":"38","key":"5544_CR9","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38):2712. https:\/\/doi.org\/10.1126\/sciadv.abd2712.","journal-title":"Sci Adv"},{"issue":"7670","key":"5544_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature23669","volume":"549","author":"R Mezzadra","year":"2017","unstructured":"Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549(7670):106\u201310.","journal-title":"Nature"},{"issue":"7718","key":"5544_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382\u20136.","journal-title":"Nature"},{"issue":"2","key":"5544_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414-427.e13.","journal-title":"Cell"},{"issue":"1","key":"5544_CR13","doi-asserted-by":"publisher","first-page":"6830","DOI":"10.1038\/s41467-024-51242-8","volume":"15","author":"Z Shu","year":"2024","unstructured":"Shu Z, Dwivedi B, Switchenko JM, Yu DS, Deng X, et al. PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer. Nat Commun. 2024;15(1):6830. https:\/\/doi.org\/10.1038\/s41467-024-51242-8.","journal-title":"Nat Commun"},{"issue":"1","key":"5544_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5483\/BMBRep.2021.54.1.241","volume":"54","author":"P Yadollahi","year":"2021","unstructured":"Yadollahi P, Jeon YK, Ng WL, Choi I. Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity. BMB Rep. 2021;54(1):12\u201320.","journal-title":"BMB Rep"},{"issue":"5","key":"5544_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1$$\\alpha $$, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390.","journal-title":"J Exp Med"},{"issue":"9","key":"5544_CR16","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Dacic S, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project. J Thorac Oncol. 2018;13(9):1302\u201311. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.013.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"5544_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.18.02276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028 and KEYNOTE-158. J Clin Oncol. 2019;37(4):318\u201327. https:\/\/doi.org\/10.1200\/JCO.18.02276.","journal-title":"J Clin Oncol"},{"key":"5544_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","volume":"8","author":"HL Williams","year":"2024","unstructured":"Williams HL, Frei AL, Koessler T, Berger MD, Dawson H, Michielin O, et al. The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition. Npj Precis Oncol. 2024;8:178. https:\/\/doi.org\/10.1038\/s41698-024-00671-1.","journal-title":"Npj Precis Oncol"},{"issue":"8","key":"5544_CR19","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1172\/JCI126022","volume":"129","author":"LC Chan","year":"2019","unstructured":"Chan LC, Li CW, Xia W, et al. IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129(8):3324\u201338.","journal-title":"J Clin Invest"},{"issue":"3","key":"5544_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","volume":"580","author":"SJ Lee","year":"2006","unstructured":"Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-$$\\gamma $$-induced upregulation of B7\u2013H1 (CD274) in cancer cells. FEBS Lett. 2006;580(3):755\u201362.","journal-title":"FEBS Lett"},{"issue":"127","key":"5544_CR21","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7\u2013H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3003689.","journal-title":"Sci Transl Med"},{"issue":"200","key":"5544_CR22","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med. 2013;5(200):200ra116. https:\/\/doi.org\/10.1126\/scitranslmed.3006504.","journal-title":"Sci Transl Med"},{"issue":"6","key":"5544_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540-1554.e12. https:\/\/doi.org\/10.1016\/j.cell.2016.11.022.","journal-title":"Cell"},{"issue":"7528","key":"5544_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371. https:\/\/doi.org\/10.1038\/nature13954.","journal-title":"Nature"},{"key":"5544_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626","volume":"11","author":"F Antonangeli","year":"2020","unstructured":"Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F. Regulation of PD-L1 expression by NF-$$\\kappa $$B in cancer. Front Immunol. 2020;11:584626. https:\/\/doi.org\/10.3389\/fimmu.2020.584626.","journal-title":"Front Immunol"},{"issue":"2","key":"5544_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00262-017-2086-8","volume":"67","author":"N Li","year":"2018","unstructured":"Li N, Wang J, Zhang N, Zhuang M, Zou J, Tao L, et al. Cross-talk between TNF-$$\\alpha $$ and IFN-$$\\gamma $$ signaling in induction of B7\u2013H1 expression in hepatocellular carcinoma cells. Cancer Immunol Immunother. 2018;67(2):271\u201383. https:\/\/doi.org\/10.1007\/s00262-017-2086-8.","journal-title":"Cancer Immunol Immunother"},{"key":"5544_CR27","doi-asserted-by":"publisher","first-page":"1192861","DOI":"10.3389\/fimmu.2023.1192861","volume":"14","author":"A Hirayama","year":"2023","unstructured":"Hirayama A, Tanaka K, Tsutsumi H, Nakanishi T, Yamashita S, Mizusaki S, et al. Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1$$\\beta $$. Front Immunol. 2023;14:1192861. https:\/\/doi.org\/10.3389\/fimmu.2023.1192861.","journal-title":"Front Immunol"},{"issue":"3","key":"5544_CR28","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"11","key":"5544_CR29","first-page":"20628","volume":"234","author":"Z Li","year":"2019","unstructured":"Li Z, Chan KTH, Ma X, et al. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5. J Cell Physiol. 2019;234(11):20628\u201338.","journal-title":"J Cell Physiol"},{"key":"5544_CR30","first-page":"6613521","volume":"2021","author":"Y Gao","year":"2021","unstructured":"Gao Y, Zhu Y, Zhang Z, et al. Cancer-associated fibroblasts promote the upregulation of PD-L1 expression in colorectal cancer. J Immunol Res. 2021;2021:6613521.","journal-title":"J Immunol Res"},{"issue":"2","key":"5544_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbrc.2017.02.128","volume":"486","author":"H Liu","year":"2017","unstructured":"Liu H, Shen J, Lu K. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. Biochem Biophys Res Commun. 2017;486(2):239\u201344. https:\/\/doi.org\/10.1016\/j.bbrc.2017.02.128.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"5544_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150846","volume":"132","author":"CM Bailey","year":"2022","unstructured":"Bailey CM, Liu Y, Peng G. Targeting HIF-1$$\\alpha $$ abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J Clin Invest. 2022;132(9):e150846. https:\/\/doi.org\/10.1172\/JCI150846.","journal-title":"J Clin Invest"},{"issue":"6","key":"5544_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010151","volume":"13","author":"Y Yu","year":"2025","unstructured":"Yu Y, Sun R, Hu F, et al. Hypoxia upregulates the expression of PD-L1 via NPM1 in breast cancer. J Immunother Cancer. 2025;13(6):e010151. https:\/\/doi.org\/10.1136\/jitc-2024-010151.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"5544_CR34","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.3390\/ijms25073735","volume":"25","author":"J Sun","year":"2024","unstructured":"Sun J, Zhao Z, Lu J, An W, Zhang Y, Li W, et al. The tumor microenvironment mediates the HIF-1alpha\/PD-L1 pathway to promote immune escape in colorectal cancer. Int J Mol Sci. 2024;25(7):3735. https:\/\/doi.org\/10.3390\/ijms25073735.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5544_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41467-024-54132-1","volume":"16","author":"HJ Hwang","year":"2025","unstructured":"Hwang HJ, Kang D, Shin J, Jung J, Ko S, Jung KH, et al. Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation. Nat Commun. 2025;16(1):353. https:\/\/doi.org\/10.1038\/s41467-024-54132-1.","journal-title":"Nat Commun"},{"key":"5544_CR36","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8:1751. https:\/\/doi.org\/10.1038\/s41467-017-01883-9.","journal-title":"Nat Commun"},{"issue":"19","key":"5544_CR37","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458\u201368. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1258.","journal-title":"Cancer Res"},{"issue":"14","key":"5544_CR38","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3215.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"5544_CR39","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","volume":"23","author":"HD Skinner","year":"2017","unstructured":"Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, et al. Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res. 2017;23(11):2713\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2586.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5544_CR40","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, de Carn\u00e9 TS, Rana S, et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity. 2017;47(6):1083-1099.e6.","journal-title":"Immunity"},{"issue":"17","key":"5544_CR41","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","volume":"21","author":"K Ota","year":"2015","unstructured":"Ota K, Azuma K, Kawahara A, et al. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Clin Cancer Res. 2015;21(17):4014\u201321.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5544_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/path.5280","volume":"249","author":"TS Stutvoet","year":"2019","unstructured":"Stutvoet TS, Kol A, de Vries EGE, de Bruyn M, Fehrmann RSN, Terpstra MM, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. J Pathol. 2019;249(1):52\u201364. https:\/\/doi.org\/10.1002\/path.5280.","journal-title":"J Pathol"},{"issue":"2","key":"5544_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76(2):227\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3362.","journal-title":"Cancer Res"},{"issue":"13","key":"5544_CR44","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","volume":"20","author":"M Atefi","year":"2014","unstructured":"Atefi M, Avramis E, Lassen A, Wong DJL, Robert L, Foulad D, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014;20(13):3446\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2797.","journal-title":"Clin Cancer Res"},{"issue":"7607","key":"5544_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers. Nature. 2016;534(7607):402\u20136. https:\/\/doi.org\/10.1038\/nature18294.","journal-title":"Nature"},{"issue":"1","key":"5544_CR46","first-page":"1","volume":"10","author":"X Ju","year":"2020","unstructured":"Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am J Cancer Res. 2020;10(1):1\u201311.","journal-title":"Am J Cancer Res"},{"issue":"12","key":"5544_CR47","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1038\/s41388-021-01689-6","volume":"40","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li X, Zhang H, et al. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. Oncogene. 2021;40(12):2230\u201342.","journal-title":"Oncogene"},{"key":"5544_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101049","volume":"57","author":"Z Cai","year":"2024","unstructured":"Cai Z, Zhai X, Xu J, Hong T, Yang K, Min S, et al. ELAVL1 regulates PD-L1 mRNA stability to disrupt the infiltration of CD4-positive T cells in prostate cancer. Neoplasia. 2024;57:101049. https:\/\/doi.org\/10.1016\/j.neo.2024.101049.","journal-title":"Neoplasia"},{"issue":"6","key":"5544_CR49","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/cas.16136","volume":"115","author":"QZ Liu","year":"2024","unstructured":"Liu QZ, Zhang N, Chen JY, Xie Y, Li J, Zhang Y, et al. WTAP-induced N6-methyladenosine of PD-L1 blocked T-cell-mediated antitumor activity under hypoxia in colorectal cancer. Cancer Sci. 2024;115(6):1749\u201362. https:\/\/doi.org\/10.1111\/cas.16136.","journal-title":"Cancer Sci"},{"issue":"1","key":"5544_CR50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13578-023-01137-w","volume":"13","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Yang Z, Hao X, Dandreo LJ, He L, Zhang Y, et al. Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling. Cell Biosci. 2023;13(1):192. https:\/\/doi.org\/10.1186\/s13578-023-01137-w.","journal-title":"Cell Biosci"},{"issue":"7","key":"5544_CR51","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.molmed.2024.04.008","volume":"30","author":"A Arthur","year":"2024","unstructured":"Arthur A, Lacroix A, Boufroura FZ, Squadrito ML, Bensaude O, Van den Eynde BJ, et al. PD-L1 at the crossroad between RNA metabolism and immunosuppression. Trends Mol Med. 2024;30(7):620\u201332. https:\/\/doi.org\/10.1016\/j.molmed.2024.04.008.","journal-title":"Trends Mol Med"},{"issue":"1","key":"5544_CR52","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","volume":"9","author":"JM Hsu","year":"2018","unstructured":"Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9(1):1908. https:\/\/doi.org\/10.1038\/s41467-018-04313-6.","journal-title":"Nat Commun"},{"issue":"6","key":"5544_CR53","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925\u201339.","journal-title":"Cancer Cell"},{"issue":"3","key":"5544_CR54","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.gendis.2022.01.002","volume":"10","author":"P Ding","year":"2023","unstructured":"Ding P, Wang W, Wang J, Yang Z, Xie C. Emerging role of ubiquitination\/deubiquitination modification of PD-1\/PD-L1 in cancer immunotherapy. Genes Dis. 2023;10(3):848\u201363. https:\/\/doi.org\/10.1016\/j.gendis.2022.01.002.","journal-title":"Genes Dis"},{"issue":"4","key":"5544_CR55","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao H, Lan J, Li C, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 2019;3(4):306\u201317. https:\/\/doi.org\/10.1038\/s41551-019-0375-6.","journal-title":"Nat Biomed Eng"},{"issue":"7686","key":"5544_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91\u20135. https:\/\/doi.org\/10.1038\/nature25015.","journal-title":"Nature"},{"issue":"1","key":"5544_CR57","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1038\/s41467-021-25662-9","volume":"12","author":"Y Ren","year":"2021","unstructured":"Ren Y, Qian Y, Ai L, Xie Y, Gao Y, Zhuang Z, et al. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity. Nat Commun. 2021;12(1):5405. https:\/\/doi.org\/10.1038\/s41467-021-25662-9.","journal-title":"Nat Commun"},{"key":"5544_CR58","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, Dong C, Xu H, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11:955. https:\/\/doi.org\/10.1038\/s41419-020-03140-2.","journal-title":"Cell Death Dis"},{"issue":"1","key":"5544_CR59","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 2019;15(1):42\u201350. https:\/\/doi.org\/10.1038\/s41589-018-0161-x.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"5544_CR60","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.celrep.2018.06.066","volume":"24","author":"J Monypenny","year":"2018","unstructured":"Monypenny J, Milewicz H, Flores-Borja F, Weitsman G, Cheung A, Chowdhury R, et al. ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation. Cell Rep. 2018;24(3):630\u201341. https:\/\/doi.org\/10.1016\/j.celrep.2018.06.066.","journal-title":"Cell Rep"},{"issue":"1","key":"5544_CR61","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1038\/s41467-024-48597-3","volume":"15","author":"X Xu","year":"2024","unstructured":"Xu X, Xie T, Zhou M, Sun Y, Wang F, Tian Y, et al. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation. Nat Commun. 2024;15(1):4237. https:\/\/doi.org\/10.1038\/s41467-024-48597-3.","journal-title":"Nat Commun"},{"issue":"7","key":"5544_CR62","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2326-6066.CIR-22-0953","volume":"11","author":"EY Lemma","year":"2023","unstructured":"Lemma EY, Letian A, Altorki NK, McGraw TE. Regulation of PD-L1 trafficking from synthesis to degradation. Cancer Immunol Res. 2023;11(7):866\u201374. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0953.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"5544_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1515\/oncologie-2024-0377","volume":"27","author":"L Zhang","year":"2025","unstructured":"Zhang L, He S, Wu L, Wang X, Bai Y. Current advancements in PD-L1 modulation by CMTM6 in malignant tumors. Oncologie. 2025;27(1):45\u201355. https:\/\/doi.org\/10.1515\/oncologie-2024-0377.","journal-title":"Oncologie"},{"key":"5544_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.971428","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang T, Yu H, Dai X, Zhang X. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. Front Immunol. 2022;13:971428. https:\/\/doi.org\/10.3389\/fimmu.2022.971428.","journal-title":"Front Immunol"},{"issue":"23","key":"5544_CR65","doi-asserted-by":"publisher","first-page":"467","DOI":"10.21037\/atm.2017.09.32","volume":"5","author":"D Imamovic","year":"2017","unstructured":"Imamovic D, Vranic S. Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors. Ann Transl Med. 2017;5(23):467. https:\/\/doi.org\/10.21037\/atm.2017.09.32.","journal-title":"Ann Transl Med"},{"key":"5544_CR66","doi-asserted-by":"publisher","first-page":"5497015","DOI":"10.1155\/2020\/5497015","volume":"2020","author":"SM Li","year":"2020","unstructured":"Li SM, Zhou J, Wang Y, Nie RC, Chen JW, Xie D. Recent findings in the posttranslational modifications of PD-L1. J Oncol. 2020;2020:5497015. https:\/\/doi.org\/10.1155\/2020\/5497015.","journal-title":"J Oncol"},{"issue":"11","key":"5544_CR67","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3390\/cancers17111747","volume":"17","author":"M Mani","year":"2025","unstructured":"Mani M, Park JW, Martin TFJ. Regulatory mechanisms and therapeutic targeting of PD-L1 trafficking and stability in cancer immunotherapy. Cancers (Basel). 2025;17(11):1747. https:\/\/doi.org\/10.3390\/cancers17111747.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5544_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12951-025-03171-x","volume":"23","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Liu D, Yang W, He W, Yan J, Yao L. Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity. J Nanobiotechnol. 2025;23(1):79. https:\/\/doi.org\/10.1186\/s12951-025-03171-x.","journal-title":"J Nanobiotechnol"},{"key":"5544_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01681-w","author":"JJ Peng","year":"2025","unstructured":"Peng JJ, Shao M, Li YY, Feng J, Zhang XT, Xu C, et al. MS1-96 induces HIP1R-dependent PD-L1 degradation and promotes antitumor immunity in colorectal cancer. Acta Pharmacol Sin. 2025. https:\/\/doi.org\/10.1038\/s41401-025-01681-w.","journal-title":"Acta Pharmacol Sin"},{"key":"5544_CR70","doi-asserted-by":"publisher","first-page":"1230135","DOI":"10.3389\/fimmu.2023.1230135","volume":"14","author":"C Feng","year":"2023","unstructured":"Feng C, Tang J, Xu J, et al. Regulation of post-translational modification of PD-L1 and application in tumor therapy. Front Immunol. 2023;14:1230135. https:\/\/doi.org\/10.3389\/fimmu.2023.1230135.","journal-title":"Front Immunol"},{"issue":"23","key":"5544_CR71","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76(23):6964\u201374.","journal-title":"Cancer Res"},{"key":"5544_CR72","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/sigtrans.2016.30","volume":"1","author":"HB Gupta","year":"2016","unstructured":"Gupta HB, Clark CA, Yuan B, et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct Target Ther. 2016;1:16030.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"5544_CR73","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800. https:\/\/doi.org\/10.1038\/nm730.","journal-title":"Nat Med"},{"issue":"19","key":"5544_CR74","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293\u20137. https:\/\/doi.org\/10.1073\/pnas.192461099.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"5544_CR75","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1200690.","journal-title":"N Engl J Med"},{"issue":"26","key":"5544_CR76","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1200694.","journal-title":"N Engl J Med"},{"issue":"4","key":"5544_CR77","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"5544_CR78","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014.","journal-title":"Immunity"},{"issue":"6382","key":"5544_CR79","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"5544_CR80","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fonc.2018.00386","volume":"8","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol. 2018;8:386. https:\/\/doi.org\/10.3389\/fonc.2018.00386.","journal-title":"Front Oncol"},{"issue":"3","key":"5544_CR81","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","volume":"9","author":"S Jalali","year":"2019","unstructured":"Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, et al. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J. 2019;9(3):22. https:\/\/doi.org\/10.1038\/s41408-019-0185-9.","journal-title":"Blood Cancer J"},{"issue":"5","key":"5544_CR82","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/cancers11050624","volume":"11","author":"D Lecis","year":"2019","unstructured":"Lecis D, Sangaletti S, Colombo MP, Chiodoni C. Immune checkpoint ligand reverse signaling: looking back to go forward in cancer therapy. Cancers (Basel). 2019;11(5):624. https:\/\/doi.org\/10.3390\/cancers11050624.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"5544_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101047","volume":"14","author":"J Wang","year":"2021","unstructured":"Wang J, Zeng H, Zhang H, Han Y. The role of exosomal PD-L1 in tumor immunotherapy. Transl Oncol. 2021;14(5):101047. https:\/\/doi.org\/10.1016\/j.tranon.2021.101047.","journal-title":"Transl Oncol"},{"key":"5544_CR84","doi-asserted-by":"publisher","first-page":"8839978","DOI":"10.1155\/2021\/8839978","volume":"2021","author":"S Ayala-Mar","year":"2021","unstructured":"Ayala-Mar S, Donoso-Quezada J, Gonz\u00e1lez-Valdez J. Clinical implications of exosomal PD-L1 in cancer immunotherapy. J Immunol Res. 2021;2021:8839978. https:\/\/doi.org\/10.1155\/2021\/8839978.","journal-title":"J Immunol Res"},{"key":"5544_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176831","volume":"979","author":"J Liu","year":"2024","unstructured":"Liu J, Qin J, Liang L, Zhang X, Gao J, Hao Y, et al. Novel insights into the regulation of exosomal PD-L1 in cancer: from generation to clinical application. Eur J Pharmacol. 2024;979:176831. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176831.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"5544_CR86","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/1750743X.2025.2539060","volume":"17","author":"Z Li","year":"2025","unstructured":"Li Z, Zhang S, Wang Y, Yan Y. The role of exosomal PD-L1 in NSCLC immunotherapy. Immunotherapy. 2025;17(10):715\u201325. https:\/\/doi.org\/10.1080\/1750743X.2025.2539060.","journal-title":"Immunotherapy"},{"issue":"1","key":"5544_CR87","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12935-025-03806-x","volume":"25","author":"C Lu","year":"2025","unstructured":"Lu C, Tufail M, Jiang CH, Li N. Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects. Cancer Cell Int. 2025;25(1):234. https:\/\/doi.org\/10.1186\/s12935-025-03806-x.","journal-title":"Cancer Cell Int"},{"key":"5544_CR88","doi-asserted-by":"publisher","first-page":"1603855","DOI":"10.3389\/fimmu.2025.1603855","volume":"16","author":"T Kansha","year":"2025","unstructured":"Kansha T, Ma X, Wang H, Yu X, Song Y, Guo Z, et al. Exosomal PD-L1 detection in cancer: predictive biomarker for response to immune checkpoint blockade therapy. Front Immunol. 2025;16:1603855. https:\/\/doi.org\/10.3389\/fimmu.2025.1603855.","journal-title":"Front Immunol"},{"issue":"7","key":"5544_CR89","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/cimb47070525","volume":"47","author":"LD Dragu","year":"2025","unstructured":"Dragu LD, Chivu-Economescu M, Pitica IM, Matei L, Bleotu C, Diaconu CC, et al. Targeting exosomal PD-L1 as a new frontier in cancer immunotherapy. Curr Issues Mol Biol. 2025;47(7):525. https:\/\/doi.org\/10.3390\/cimb47070525.","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"5544_CR90","doi-asserted-by":"publisher","first-page":"1710899","DOI":"10.1080\/20013078.2019.1710899","volume":"9","author":"M Cordonnier","year":"2020","unstructured":"Cordonnier M, Nardin C, Chanteloup G, Derangere V, Algros MP, Arnould L, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles. 2020;9(1):1710899. https:\/\/doi.org\/10.1080\/20013078.2019.1710899.","journal-title":"J Extracell Vesicles"},{"issue":"4","key":"5544_CR91","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","volume":"24","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24(4):896\u2013905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2664.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5544_CR92","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/bjc.2018.9","volume":"118","author":"M Del Re","year":"2018","unstructured":"Del Re M, Marconcini R, Pasquini G, Rofi E, Vivaldi C, Bloise F, et al. PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. Br J Cancer. 2018;118(6):820\u20134. https:\/\/doi.org\/10.1038\/bjc.2018.9.","journal-title":"Br J Cancer"},{"issue":"9","key":"5544_CR93","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao Y, Nihira NT, Bu X, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22(9):1064\u201375.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"5544_CR94","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00262-022-03176-7","volume":"71","author":"L Qu","year":"2022","unstructured":"Qu L, Zhang Y, Wang J, et al. The nuclear transportation of PD-L1 and the function in tumor immunity and progression. Cancer Immunol Immunother. 2022;71(5):1011\u201320.","journal-title":"Cancer Immunol Immunother"},{"key":"5544_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70422","author":"J Tian","year":"2026","unstructured":"Tian J, Zhang X, Sun Y, et al. Programmed death-ligand 1 nuclear translocation: a novel perspective from membrane localization to nuclear function. Int J Cancer. 2026. https:\/\/doi.org\/10.1002\/ijc.70422.","journal-title":"Int J Cancer"},{"issue":"1","key":"5544_CR96","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"TS Nowicki","year":"2018","unstructured":"Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018;24(1):47\u201353. https:\/\/doi.org\/10.1097\/PPO.0000000000000303.","journal-title":"Cancer J"},{"key":"5544_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101234","volume":"69","author":"T Nosaka","year":"2025","unstructured":"Nosaka T, Ohtani M, Yamashita J, Murata Y, Akazawa Y, Tanaka T, et al. PD-L1(+) tumor-associated macrophages induce CD8(+) T cell exhaustion in hepatocellular carcinoma. Neoplasia. 2025;69:101234. https:\/\/doi.org\/10.1016\/j.neo.2025.101234.","journal-title":"Neoplasia"},{"key":"5544_CR98","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"JY Sun","year":"2020","unstructured":"Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res. 2020;8:35. https:\/\/doi.org\/10.1186\/s40364-020-00212-5.","journal-title":"Biomark Res"},{"key":"5544_CR99","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fphar.2020.00441","volume":"11","author":"LC de Erauso","year":"2020","unstructured":"de Erauso LC, Zuazo M, Arasanz H, et al. Resistance to PD-L1\/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon? Front Pharmacol. 2020;11:441. https:\/\/doi.org\/10.3389\/fphar.2020.00441.","journal-title":"Front Pharmacol"},{"key":"5544_CR100","doi-asserted-by":"publisher","first-page":"1658795","DOI":"10.3389\/fimmu.2025.1658795","volume":"16","author":"W Xia","year":"2025","unstructured":"Xia W, Zhang X, Wang Y, Huang Z, Guo X, Fang L. Progress in targeting tumor-associated macrophages in cancer immunotherapy. Front Immunol. 2025;16:1658795. https:\/\/doi.org\/10.3389\/fimmu.2025.1658795.","journal-title":"Front Immunol"},{"issue":"1","key":"5544_CR101","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei L, Wang H, Zhang Y, et al. Roles of cancer-associated fibroblasts (CAFs) in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):29. https:\/\/doi.org\/10.1186\/s12943-023-01731-z.","journal-title":"Mol Cancer"},{"key":"5544_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217475","volume":"612","author":"R Wei","year":"2025","unstructured":"Wei R, Song J, Liu C, Zhao Z, Liu X, Yamamoto M, et al. FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity. Cancer Lett. 2025;612:217475. https:\/\/doi.org\/10.1016\/j.canlet.2025.217475.","journal-title":"Cancer Lett"},{"key":"5544_CR103","doi-asserted-by":"publisher","first-page":"1635915","DOI":"10.3389\/fcell.2025.1635915","volume":"13","author":"Z Yang","year":"2025","unstructured":"Yang Z, Wang X, Zhu X, Li L, Zeng X, Ren J, et al. CD248 induces PD-L1 expression on cancer-associated fibroblasts to promote NSCLC immune escape. Front Cell Dev Biol. 2025;13:1635915. https:\/\/doi.org\/10.3389\/fcell.2025.1635915.","journal-title":"Front Cell Dev Biol"},{"key":"5544_CR104","doi-asserted-by":"publisher","first-page":"1617662","DOI":"10.3389\/fimmu.2025.1617662","volume":"16","author":"J Luo","year":"2025","unstructured":"Luo J, Xiang X, Gong G, Jiang L. Cancer-associated fibroblast-mediated immune evasion: molecular mechanisms of stromal-immune crosstalk in the tumor microenvironment. Front Immunol. 2025;16:1617662. https:\/\/doi.org\/10.3389\/fimmu.2025.1617662.","journal-title":"Front Immunol"},{"issue":"11","key":"5544_CR105","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1007\/s00262-023-03531-2","volume":"72","author":"K Kawasaki","year":"2023","unstructured":"Kawasaki K, Noma K, Kato T, Ohara T, Tanabe S, Takeda Y, et al. PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer. Cancer Immunol Immunother. 2023;72(11):3787\u2013802. https:\/\/doi.org\/10.1007\/s00262-023-03531-2.","journal-title":"Cancer Immunol Immunother"},{"key":"5544_CR106","doi-asserted-by":"publisher","first-page":"1635771","DOI":"10.3389\/fimmu.2025.1635771","volume":"16","author":"G Ruan","year":"2025","unstructured":"Ruan G, Wang X, Ou H, Guo D. Cancer-associated fibroblasts: dual roles from senescence sentinels to death regulators and new dimensions in therapy. Front Immunol. 2025;16:1635771. https:\/\/doi.org\/10.3389\/fimmu.2025.1635771.","journal-title":"Front Immunol"},{"issue":"5","key":"5544_CR107","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.it.2019.03.004","volume":"40","author":"M Wagner","year":"2019","unstructured":"Wagner M, Koyasu S. Cancer immunoediting by innate lymphoid cells. Trends Immunol. 2019;40(5):415\u201330. https:\/\/doi.org\/10.1016\/j.it.2019.03.004.","journal-title":"Trends Immunol"},{"issue":"10","key":"5544_CR108","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.trecan.2022.06.010","volume":"8","author":"M Wagner","year":"2022","unstructured":"Wagner M, Koyasu S. Cancer immunosurveillance by ILC2s. Trends Cancer. 2022;8(10):792\u20134. https:\/\/doi.org\/10.1016\/j.trecan.2022.06.010.","journal-title":"Trends Cancer"},{"issue":"8045","key":"5544_CR109","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-024-08194-2","volume":"637","author":"M Wagner","year":"2025","unstructured":"Wagner M, Nishikawa H, Koyasu S. Reinventing type 2 immunity in cancer. Nature. 2025;637(8045):296\u2013303. https:\/\/doi.org\/10.1038\/s41586-024-08194-2.","journal-title":"Nature"},{"issue":"7","key":"5544_CR110","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41590-021-00943-z","volume":"22","author":"N Jacquelot","year":"2021","unstructured":"Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22(7):851\u201364. https:\/\/doi.org\/10.1038\/s41590-021-00943-z.","journal-title":"Nat Immunol"},{"issue":"8","key":"5544_CR111","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/j.celrep.2020.01.103","volume":"30","author":"M Wagner","year":"2020","unstructured":"Wagner M, Ealey KN, Tetsu H, Kiniwa T, Motomura Y, Moro K, et al. Tumor-derived lactic acid contributes to the paucity of intratumoral ILC2s. Cell Rep. 2020;30(8):2743-2757.e5. https:\/\/doi.org\/10.1016\/j.celrep.2020.01.103.","journal-title":"Cell Rep"},{"key":"5544_CR112","doi-asserted-by":"publisher","first-page":"1236301","DOI":"10.3389\/fimmu.2023.1236301","volume":"14","author":"M Marciniak","year":"2023","unstructured":"Marciniak M, Wagner M. Innate lymphoid cells and tumor-derived lactic acid: novel contenders in an enduring game. Front Immunol. 2023;14:1236301. https:\/\/doi.org\/10.3389\/fimmu.2023.1236301.","journal-title":"Front Immunol"},{"issue":"2","key":"5544_CR113","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40(2):201-218.e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.001.","journal-title":"Cancer Cell"},{"key":"5544_CR114","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501. https:\/\/doi.org\/10.1038\/ncomms10501.","journal-title":"Nat Commun"},{"issue":"23","key":"5544_CR115","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.3390\/cancers17233849","volume":"17","author":"S Png","year":"2025","unstructured":"Png S, Tadepalli S, Graves EE. Radiation-induced immune responses from the tumor microenvironment to systemic immunity. Cancers (Basel). 2025;17(23):3849. https:\/\/doi.org\/10.3390\/cancers17233849.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5544_CR116","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261779","volume":"6","author":"G Shayan","year":"2017","unstructured":"Shayan G, Srivastava R, Li J, et al. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology. 2017;6(1):e1261779. https:\/\/doi.org\/10.1080\/2162402X.2016.1261779.","journal-title":"Oncoimmunology"},{"issue":"5","key":"5544_CR117","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ijrobp.2023.12.046","volume":"118","author":"AJ Wisdom","year":"2024","unstructured":"Wisdom AJ, Barker CA, Chang JY, Demaria S, Formenti S, Grassberger C, et al. The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives. Int J Radiat Oncol Biol Phys. 2024;118(5):1404\u201321. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.046.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5544_CR118","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/cancers17030391","volume":"17","author":"SSY Lee","year":"2025","unstructured":"Lee SSY, Pagacz J, Averbek S, Scholten D, Liu Y, Kron SJ. Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation. Cancers (Basel). 2025;17(3):391. https:\/\/doi.org\/10.3390\/cancers17030391.","journal-title":"Cancers (Basel)"},{"key":"5544_CR119","doi-asserted-by":"publisher","first-page":"1382256","DOI":"10.3389\/fphar.2024.1382256","volume":"15","author":"Z Li","year":"2024","unstructured":"Li Z, Duan D, Li L, Peng D, Ming Y, Ni R, et al. Tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress. Front Pharmacol. 2024;15:1382256. https:\/\/doi.org\/10.3389\/fphar.2024.1382256.","journal-title":"Front Pharmacol"},{"key":"5544_CR120","doi-asserted-by":"publisher","first-page":"1668199","DOI":"10.3389\/fimmu.2025.1668199","volume":"16","author":"J Xu","year":"2025","unstructured":"Xu J, Chen Z, Qin Y, Tan L, Xu S. Nano-strategies targeting cancer-associated fibroblasts to enhance immunotherapy and reverse resistance. Front Immunol. 2025;16:1668199. https:\/\/doi.org\/10.3389\/fimmu.2025.1668199.","journal-title":"Front Immunol"},{"key":"5544_CR121","doi-asserted-by":"publisher","first-page":"38","DOI":"10.20517\/cdr.2025.97","volume":"8","author":"J Wu","year":"2025","unstructured":"Wu J, Zhang PF, Zeng Y, Hai YN, Zhang KM, Dong S, et al. Effects of FAP+ cancer-associated fibroblasts on anti-PD-1 immunotherapy and CD4+ T cell polarization in gastric cancer. Cancer Drug Resist. 2025;8:38. https:\/\/doi.org\/10.20517\/cdr.2025.97.","journal-title":"Cancer Drug Resist"},{"issue":"6","key":"5544_CR122","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/his.14018","volume":"76","author":"BM Koomen","year":"2020","unstructured":"Koomen BM, Badrising SK, van den Heuvel MM, Willems SM. Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review. Histopathology. 2020;76(6):793\u2013802. https:\/\/doi.org\/10.1111\/his.14018.","journal-title":"Histopathology"},{"issue":"4","key":"5544_CR123","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"5544_CR124","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2228.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"5544_CR125","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5.","journal-title":"Lancet Oncol"},{"issue":"16","key":"5544_CR126","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3390\/cancers17162639","volume":"17","author":"IP Trontzas","year":"2025","unstructured":"Trontzas IP, Syrigos KN. Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies. Cancers (Basel). 2025;17(16):2639. https:\/\/doi.org\/10.3390\/cancers17162639.","journal-title":"Cancers (Basel)"},{"key":"5544_CR127","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.lungcan.2020.07.012","volume":"147","author":"S Ben Dori","year":"2020","unstructured":"Ben Dori S, Aizic A, Sabo E, Hershkovitz D. Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer. Lung Cancer. 2020;147:91\u20138.","journal-title":"Lung Cancer"},{"issue":"2","key":"5544_CR128","doi-asserted-by":"crossref","first-page":"900","DOI":"10.21037\/tlcr-20-1217","volume":"10","author":"L Zhao","year":"2021","unstructured":"Zhao L, Li X, Zhao S, et al. Concordance of PD-L1 status between image-guided percutaneous biopsies and matched surgical specimens in non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(2):900\u20139.","journal-title":"Transl Lung Cancer Res"},{"issue":"21","key":"5544_CR129","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-18-0309","volume":"24","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, et al. Quantitative spatial profiling of PD-1\/PD-L1 interaction and HLA-DR\/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin Cancer Res. 2018;24(21):5250\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0309.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"5544_CR130","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.3390\/cancers16244145","volume":"16","author":"I Lubo","year":"2024","unstructured":"Lubo I, Hernandez S, Wistuba II, Solis Soto LM. Novel spatial approaches to dissect the lung cancer immune microenvironment. Cancers (Basel). 2024;16(24):4145. https:\/\/doi.org\/10.3390\/cancers16244145.","journal-title":"Cancers (Basel)"},{"key":"5544_CR131","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.2147\/CMAR.S167400","volume":"10","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Zhao F, Li Z, Yu J. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res. 2018;10:2475\u201388. https:\/\/doi.org\/10.2147\/CMAR.S167400.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"5544_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","volume":"5","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med. 2024;5(7):101621. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101621.","journal-title":"Cell Rep Med"},{"issue":"7528","key":"5544_CR133","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137. https:\/\/doi.org\/10.1038\/nature14011.","journal-title":"Nature"},{"issue":"8","key":"5544_CR134","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340. https:\/\/doi.org\/10.1172\/JCI91190.","journal-title":"J Clin Invest"},{"issue":"6411","key":"5544_CR135","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593. https:\/\/doi.org\/10.1126\/science.aar3593.","journal-title":"Science"},{"issue":"3","key":"5544_CR136","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596-614.e14. https:\/\/doi.org\/10.1016\/j.cell.2021.01.002.","journal-title":"Cell"},{"issue":"12","key":"5544_CR137","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/jpm15120596","volume":"15","author":"M Agostini","year":"2025","unstructured":"Agostini M, Traldi P, Hamdan M. The search for predictive biomarkers in response to immune checkpoint inhibitors and associated adverse events. J Pers Med. 2025;15(12):596. https:\/\/doi.org\/10.3390\/jpm15120596.","journal-title":"J Pers Med"},{"issue":"3","key":"5544_CR138","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350. https:\/\/doi.org\/10.1038\/s41568-019-0116-x.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"5544_CR139","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","volume":"43","author":"SL Wang","year":"2025","unstructured":"Wang SL, Chan TA. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell. 2025;43(4):641\u201364. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.006.","journal-title":"Cancer Cell"},{"issue":"Pt 2","key":"5544_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"MA Hossain","year":"2024","unstructured":"Hossain MA. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143(Pt 2):113365. https:\/\/doi.org\/10.1016\/j.intimp.2024.113365.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"5544_CR141","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275\u201387. https:\/\/doi.org\/10.1038\/nrc.2016.36.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"5544_CR142","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.7150\/jca.108163","volume":"16","author":"D Liu","year":"2025","unstructured":"Liu D, Xiao H, Xiang Y, Zhong D, Liu Y, Wang Y, et al. Strategies to overcome PD-1\/PD-L1 blockade resistance: focusing on combination with immune checkpoint blockades. J Cancer. 2025;16(11):3425\u201349. https:\/\/doi.org\/10.7150\/jca.108163.","journal-title":"J Cancer"},{"issue":"1","key":"5544_CR143","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12943-025-02400-z","volume":"24","author":"K Mandal","year":"2025","unstructured":"Mandal K, Barik GK, Santra MK. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Mol Cancer. 2025;24(1):246. https:\/\/doi.org\/10.1186\/s12943-025-02400-z.","journal-title":"Mol Cancer"},{"issue":"2","key":"5544_CR144","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","volume":"39","author":"A Mariniello","year":"2025","unstructured":"Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, et al. Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back. BioDrugs. 2025;39(2):215\u201335. https:\/\/doi.org\/10.1007\/s40259-024-00700-2.","journal-title":"BioDrugs"},{"issue":"3","key":"5544_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100425","volume":"37","author":"TN Aung","year":"2024","unstructured":"Aung TN, Bates KM, Rimm DL. High-plex assessment of biomarkers in tumors. Mod Pathol. 2024;37(3):100425. https:\/\/doi.org\/10.1016\/j.modpat.2024.100425.","journal-title":"Mod Pathol"},{"issue":"3","key":"5544_CR146","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/path.6238","volume":"262","author":"CA Jahangir","year":"2024","unstructured":"Jahangir CA, Page DB, Broeckx G, et al. Image-based multiplex immune profiling of cancer tissues: translational implications. J Pathol. 2024;262(3):271\u201388. https:\/\/doi.org\/10.1002\/path.6238.","journal-title":"J Pathol"},{"issue":"2","key":"5544_CR147","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4132\/jptm.2024.01.31","volume":"58","author":"U Cho","year":"2024","unstructured":"Cho U. Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer. J Pathol Transl Med. 2024;58(2):49\u201358. https:\/\/doi.org\/10.4132\/jptm.2024.01.31.","journal-title":"J Pathol Transl Med"},{"issue":"7","key":"5544_CR148","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88647","volume":"17","author":"M Puntambekar","year":"2025","unstructured":"Puntambekar M, Shery N, Parokkaran I, et al. Predictive biomarkers in cancer immunotherapy: a narrative review across selected solid tumors. Cureus. 2025;17(7):e88647. https:\/\/doi.org\/10.7759\/cureus.88647.","journal-title":"Cureus"},{"issue":"6","key":"5544_CR149","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/cancers16061225","volume":"16","author":"B Ponvilawan","year":"2024","unstructured":"Ponvilawan B, Khan AW, Subramanian J, Bansal D. Non-invasive predictive biomarkers for immune-related adverse events due to immune checkpoint inhibitors. Cancers (Basel). 2024;16(6):1225. https:\/\/doi.org\/10.3390\/cancers16061225.","journal-title":"Cancers (Basel)"},{"key":"5544_CR150","doi-asserted-by":"publisher","first-page":"1601266","DOI":"10.3389\/fimmu.2025.1601266","volume":"16","author":"M Ahn","year":"2025","unstructured":"Ahn M, Mun J-G, Han Y, Seo JH. Cancer cell-derived extracellular vesicles: a potential target for overcoming tumor immunotherapy resistance and immune evasion strategies. Front Immunol. 2025;16:1601266. https:\/\/doi.org\/10.3389\/fimmu.2025.1601266.","journal-title":"Front Immunol"},{"key":"5544_CR151","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s44319-024-00354-9","volume":"26","author":"NT Nihira","year":"2025","unstructured":"Nihira NT, Wu W, Hosoi M, Togashi Y, Sunada S, Miyoshi Y, et al. Nuclear PD-L1 triggers tumour-associated inflammation upon DNA damage. EMBO Rep. 2025;26:635\u201355. https:\/\/doi.org\/10.1038\/s44319-024-00354-9.","journal-title":"EMBO Rep"},{"issue":"8","key":"5544_CR152","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jtho.2022.04.009","volume":"17","author":"M Moutafi","year":"2022","unstructured":"Moutafi M, Tao W, Huang R, et al. Discovery of biomarkers of resistance to immune checkpoint blockade in NSCLC using high-plex digital spatial profiling. J Thorac Oncol. 2022;17(8):991\u20131003.","journal-title":"J Thorac Oncol"},{"issue":"22","key":"5544_CR153","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1158\/1078-0432.CCR-22-2277","volume":"28","author":"V Anagnostou","year":"2022","unstructured":"Anagnostou V, Luke JJ. Quantitative spatial profiling of TILs as the next step beyond PD-L1 testing for immune checkpoint blockade. Clin Cancer Res. 2022;28(22):4835\u20137.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5544_CR154","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011346","volume":"13","author":"J Zhang","year":"2025","unstructured":"Zhang J, Rosenthal MH, Choi H, Rimm DL, et al. Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction. J Immunother Cancer. 2025;13(8):e011346. https:\/\/doi.org\/10.1136\/jitc-2024-011346.","journal-title":"J Immunother Cancer"},{"key":"5544_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2025.100531","volume":"20","author":"HR Makhlouf","year":"2025","unstructured":"Makhlouf HR, Ossandon MR, Farahani K, Lubensky I, Harris LN. Digital pathology imaging artificial intelligence in cancer research and clinical trials: an NCI workshop report. J Pathol Inform. 2025;20:100531. https:\/\/doi.org\/10.1016\/j.jpi.2025.100531.","journal-title":"J Pathol Inform"},{"key":"5544_CR156","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10585-023-10252-4","volume":"41","author":"J Magrill","year":"2024","unstructured":"Magrill J, Moldoveanu D, Gu J, Lajoie M, et al. Mapping the single cell spatial immune landscapes of the melanoma microenvironment. Clin Exp Metastasis. 2024;41:301\u201312. https:\/\/doi.org\/10.1007\/s10585-023-10252-4.","journal-title":"Clin Exp Metastasis"},{"key":"5544_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104980","volume":"216","author":"EO Oisakede","year":"2025","unstructured":"Oisakede EO, Akinro O, Bello OJ, Analikwu CC, Egbon E, Olawade DB. Predictive models for checkpoint inhibitor response in cancer: a review of current approaches and future directions. Crit Rev Oncol Hematol. 2025;216:104980. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104980.","journal-title":"Crit Rev Oncol Hematol"},{"key":"5544_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2025.105493","volume":"320","author":"J Guedes","year":"2025","unstructured":"Guedes J, Woldmar N, Szasz AM, et al. A perspective on integrating digital pathology, proteomics, clinical data and AI analytics in cancer research. J Proteomics. 2025;320:105493. https:\/\/doi.org\/10.1016\/j.jprot.2025.105493.","journal-title":"J Proteomics"},{"key":"5544_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2023.100352","volume":"15","author":"R Rajendran","year":"2024","unstructured":"Rajendran R, Beck RC, Waskasi MM, Kelly BD, Bauer DR. Digital analysis of the prostate tumor microenvironment with high-order chromogenic multiplexing. J Pathol Inform. 2024;15:100352. https:\/\/doi.org\/10.1016\/j.jpi.2023.100352.","journal-title":"J Pathol Inform"},{"issue":"12","key":"5544_CR160","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, Cho M, Kim E, Seo Y, Cha JH. PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32(12):4235\u201355. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.026.","journal-title":"Mol Ther"},{"issue":"2","key":"5544_CR161","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MOU.0000000000001357","volume":"36","author":"GN Fanelli","year":"2026","unstructured":"Fanelli GN, Roviello G, Nesi G. The role of pathology in immunotherapy and targeted therapy for renal cell carcinoma. Curr Opin Urol. 2026;36(2):187\u201395. https:\/\/doi.org\/10.1097\/MOU.0000000000001357.","journal-title":"Curr Opin Urol"},{"issue":"5","key":"5544_CR162","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40257-025-00969-1","volume":"26","author":"CD Vestergaard","year":"2025","unstructured":"Vestergaard CD, Ellebaek E, Borch TH, et al. The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma. Am J Clin Dermatol. 2025;26(5):777\u201394. https:\/\/doi.org\/10.1007\/s40257-025-00969-1.","journal-title":"Am J Clin Dermatol"},{"key":"5544_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115555","volume":"166","author":"H Yan","year":"2025","unstructured":"Yan H, Wang Y, Zhu M, Sun D, Li H, Chen L. Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors. Int Immunopharmacol. 2025;166:115555. https:\/\/doi.org\/10.1016\/j.intimp.2025.115555.","journal-title":"Int Immunopharmacol"},{"key":"5544_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104745","volume":"212","author":"Q Xu","year":"2025","unstructured":"Xu Q, Chu J, Hu Q, Sun Y, Jiang F, Li S, et al. The role and clinical significance of tumor-draining lymph nodes in tumor progression and immunotherapy. Crit Rev Oncol Hematol. 2025;212:104745. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104745.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"5544_CR165","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.trecan.2025.04.008","volume":"11","author":"J von Renesse","year":"2025","unstructured":"von Renesse J, Lin MC, Ho PC. Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy? Trends Cancer. 2025;11(7):676\u201390. https:\/\/doi.org\/10.1016\/j.trecan.2025.04.008.","journal-title":"Trends Cancer"},{"key":"5544_CR166","doi-asserted-by":"publisher","first-page":"55","DOI":"10.20517\/cdr.2025.126","volume":"8","author":"J Lu","year":"2025","unstructured":"Lu J, Yu J, Xu T, Li Y, Chen S, Zhou Q, et al. Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update. Cancer Drug Resist. 2025;8:55. https:\/\/doi.org\/10.20517\/cdr.2025.126.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"5544_CR167","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","volume":"44","author":"H Wang","year":"2025","unstructured":"Wang H, Niu X, Jin Z, Zhang S, Fan R, Xiao H, et al. Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities. J Exp Clin Cancer Res. 2025;44(1):250. https:\/\/doi.org\/10.1186\/s13046-025-03519-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"5544_CR168","doi-asserted-by":"publisher","first-page":"1395332","DOI":"10.3389\/fimmu.2024.1395332","volume":"15","author":"MM Lu","year":"2024","unstructured":"Lu MM, Yang Y. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives. Front Immunol. 2024;15:1395332. https:\/\/doi.org\/10.3389\/fimmu.2024.1395332.","journal-title":"Front Immunol"},{"key":"5544_CR169","doi-asserted-by":"publisher","first-page":"1342728","DOI":"10.3389\/fimmu.2024.1342728","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu Y, Fu H, Hao J, Yang Z, Qiao X, Li Y, et al. Tumor-derived exosomal PD-L1: a new perspective in PD-1\/PD-L1 therapy for lung cancer. Front Immunol. 2024;15:1342728. https:\/\/doi.org\/10.3389\/fimmu.2024.1342728.","journal-title":"Front Immunol"},{"key":"5544_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115984","volume":"220","author":"D Liu","year":"2024","unstructured":"Liu D, Wen C, Chen L, Ye M, Liu H, Sun X, et al. The emerging roles of PD-L1 subcellular localization in tumor immune evasion. Biochem Pharmacol. 2024;220:115984. https:\/\/doi.org\/10.1016\/j.bcp.2023.115984.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"5544_CR171","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/1878-0261.13567","volume":"18","author":"D Schulz","year":"2024","unstructured":"Schulz D, Feulner L, Santos Rubenich D, Heimer S, Rohrmuller S, Reinders Y, et al. Subcellular localization of PD-L1 and cell-cycle-dependent expression of nuclear PD-L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy. Mol Oncol. 2024;18(2):431\u201352. https:\/\/doi.org\/10.1002\/1878-0261.13567.","journal-title":"Mol Oncol"},{"issue":"40","key":"5544_CR172","doi-asserted-by":"publisher","first-page":"27230","DOI":"10.1021\/acsnano.4c09190","volume":"18","author":"Y Lu","year":"2024","unstructured":"Lu Y, Zheng J, Lin P, Lin Y, Zheng Y, Mai Z, et al. Tumor microenvironment-derived exosomes: a double-edged sword for advanced T cell-based immunotherapy. ACS Nano. 2024;18(40):27230\u201360. https:\/\/doi.org\/10.1021\/acsnano.4c09190.","journal-title":"ACS Nano"},{"key":"5544_CR173","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s13402-026-01181-x","volume":"49","author":"Y Kui","year":"2026","unstructured":"Kui Y, Tong F, Zhang R, Dong X, Wang J. Strategies to target PD-1\/PD-L1 in the tumor microenvironment. Cell Oncol (Dordr). 2026;49:50. https:\/\/doi.org\/10.1007\/s13402-026-01181-x.","journal-title":"Cell Oncol (Dordr)"},{"key":"5544_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105218","volume":"221","author":"H Khorramdelazad","year":"2026","unstructured":"Khorramdelazad H, Arfaei R, Yaraghi P, Boroumand A, Kheyri A, Shirzad Z, et al. Integrating STING activation with programmed death-ligand 1 inhibition: novel approaches for cancer treatment. Crit Rev Oncol Hematol. 2026;221:105218. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105218.","journal-title":"Crit Rev Oncol Hematol"},{"key":"5544_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105169","volume":"220","author":"V Vohra","year":"2026","unstructured":"Vohra V, Dhanawat M, Chalotra R, Bhushan B, Garima GJ. Shaping immunotherapy through the tumor microenvironment: translational perspectives. Crit Rev Oncol Hematol. 2026;220:105169. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105169.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"17","key":"5544_CR176","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.3390\/ijms25179659","volume":"25","author":"LA Pavelescu","year":"2024","unstructured":"Pavelescu LA, Enache RM, Rosu OA, Profir M, Cretoiu SM, Gaspar BS. Predictive biomarkers and resistance mechanisms of checkpoint inhibitors in malignant solid tumors. Int J Mol Sci. 2024;25(17):9659. https:\/\/doi.org\/10.3390\/ijms25179659.","journal-title":"Int J Mol Sci"},{"key":"5544_CR177","doi-asserted-by":"publisher","first-page":"1554871","DOI":"10.3389\/fimmu.2025.1554871","volume":"16","author":"J Zhang","year":"2025","unstructured":"Zhang J, Song Z, Zhang Y, Zhang C, Xue Q, Zhang G, et al. Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer. Front Immunol. 2025;16:1554871. https:\/\/doi.org\/10.3389\/fimmu.2025.1554871.","journal-title":"Front Immunol"},{"issue":"3","key":"5544_CR178","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s10555-025-10274-2","volume":"44","author":"J Kim","year":"2025","unstructured":"Kim J, Kim HS, Nam M, Chae YK. Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates. Cancer Metastasis Rev. 2025;44(3):58. https:\/\/doi.org\/10.1007\/s10555-025-10274-2.","journal-title":"Cancer Metastasis Rev"},{"key":"5544_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S567238","volume":"15","author":"E Gariazzo","year":"2026","unstructured":"Gariazzo E, Colamartini F, Ubaldi M, Santo V, Brunetti L, Tomarelli C, et al. Emerging predictive biomarkers of immunotherapy sensitivity in patients with non-small cell lung cancer. Immunotargets Ther. 2026;15:1\u201320. https:\/\/doi.org\/10.2147\/ITT.S567238.","journal-title":"Immunotargets Ther"},{"issue":"2","key":"5544_CR180","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00428-024-04005-1","volume":"486","author":"X Matias-Guiu","year":"2025","unstructured":"Matias-Guiu X, Raspollini MR, Kulka J, Ryska A, Al Dieri R, Schirmacher P, et al. The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology. Virchows Arch. 2025;486(2):207\u201314. https:\/\/doi.org\/10.1007\/s00428-024-04005-1.","journal-title":"Virchows Arch"},{"key":"5544_CR181","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S581764","volume":"19","author":"P Cao","year":"2026","unstructured":"Cao P, Jia X, Yang Y, Wang X, Zhu J, Li X, et al. Artificial intelligence for predicting immunotherapy efficacy in non-small cell lung cancer. J Inflamm Res. 2026;19:581764. https:\/\/doi.org\/10.2147\/JIR.S581764.","journal-title":"J Inflamm Res"},{"issue":"8","key":"5544_CR182","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.5306\/wjco.v15.i8.1002","volume":"15","author":"AJ Guo","year":"2024","unstructured":"Guo AJ, Deng QY, Dong P, Zhou L, Shi L. Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors. World J Clin Oncol. 2024;15(8):1002\u201320. https:\/\/doi.org\/10.5306\/wjco.v15.i8.1002.","journal-title":"World J Clin Oncol"},{"issue":"4","key":"5544_CR183","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jjco\/hyad184","volume":"54","author":"Y Liang","year":"2024","unstructured":"Liang Y, Sato T, Inoue Y, et al. Biomarkers for immune-related adverse events in cancer immunotherapy. Jpn J Clin Oncol. 2024;54(4):365\u201375. https:\/\/doi.org\/10.1093\/jjco\/hyad184.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"5544_CR184","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.rdc.2024.01.004","volume":"50","author":"W Bracamonte-Baran","year":"2024","unstructured":"Bracamonte-Baran W, Kim ST. The Current and Future of Biomarkers of Immune Related Adverse Events. Rheum Dis Clin North Am. 2024;50(2):201\u201327. https:\/\/doi.org\/10.1016\/j.rdc.2024.01.004.","journal-title":"Rheum Dis Clin North Am"},{"issue":"13","key":"5544_CR185","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.3390\/ijms26136066","volume":"26","author":"V Ferrari","year":"2025","unstructured":"Ferrari V, Gal J, Mograbi B, Milano G. PD-L1 expression in NSCLC: clouds in a bright sky. Int J Mol Sci. 2025;26(13):6066. https:\/\/doi.org\/10.3390\/ijms26136066.","journal-title":"Int J Mol Sci"},{"key":"5544_CR186","doi-asserted-by":"publisher","first-page":"1604310","DOI":"10.3389\/fimmu.2025.1604310","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Qin D, Fu J. T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation. Front Immunol. 2025;16:1604310. https:\/\/doi.org\/10.3389\/fimmu.2025.1604310.","journal-title":"Front Immunol"},{"key":"5544_CR187","doi-asserted-by":"publisher","first-page":"1002315","DOI":"10.37349\/etat.2025.1002315","volume":"6","author":"Z Chen","year":"2025","unstructured":"Chen Z, Yu J, Guo Z, Chen S, Li Y, Zhou Q, et al. Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor. Explor Target Antitumor Ther. 2025;6:1002315. https:\/\/doi.org\/10.37349\/etat.2025.1002315.","journal-title":"Explor Target Antitumor Ther"},{"issue":"1","key":"5544_CR188","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","volume":"18","author":"L Huang","year":"2025","unstructured":"Huang L, Zhu H, Shi Y. Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000\u20132025). J Hematol Oncol. 2025;18(1):107. https:\/\/doi.org\/10.1186\/s13045-025-01734-x.","journal-title":"J Hematol Oncol"},{"key":"5544_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.825284","volume":"12","author":"NT Nihira","year":"2022","unstructured":"Nihira NT, Gao Y, Bu X, et al. Regulation of intrinsic functions of PD-L1 by post-translational modifications. Front Oncol. 2022;12:825284. https:\/\/doi.org\/10.3389\/fonc.2022.825284.","journal-title":"Front Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05544-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:22:30Z","timestamp":1790925750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05544-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":189,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5544"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05544-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1401"}}